drugset / Trial / NCT05952596
A Study to Evaluate Safety and Immunogenicity of APV006 in Healthy Adults
RandomizedParallel-groupDouble-blindPrevention
Summary
This is a single-center, randomized, active-controlled, parallel-design, double-blind, phase I study to evaluate the safety and immunogenicity of a single dose of APV006 in healthy adults.
Timeline
- Start
- 2023-07-17
- Primary completion
- 2023-10-31
- Completion
- 2024-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Infanrix hexa | Vaccine | — | — |